This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Spectrum Pharmaceuticals, Inc.
Drug Names(s): Belinostat (IV), PXD101 (Intravenous)
Description: BioMedTracker has separate drug profiles for the IV and oral formulations of PXD101. Please also see PXD101 (Oral).
PXD101 is a Class I and II histone deacetylase (HDAC) inhibitor. HDAC inhibitors represent a newmechanistic class of anti-cancer therapeutics that target HDAC enzymes, and have been shown to: arrest growth of cancer cells (including drug resistant subtypes); induce apoptosis, or programmed cell death; promote differentiation; inhibit angiogenesis; and sensitize cancer cells to overcome drug resistance when used in combination with other anti-cancer agents.
Revenue splits for this drug are BioMedTracker estimates.
In June 2004, Curagen signed a license and collaboration agreement with TopoTarget to develop PXD101. Under the terms of the agreement, Curagen acquired exclusive rights to develop, and commercialize PXD101 in North America, Asia and all other markets excluding Europe. TopoTarget retains commercialization rights in Europe. During June 2004, Curagen made a $5.0 million equity investment in, and paid a $5.0 million perpetual license fee to TopoTarget. In addition, TopoTarget was eligible to receive up to $10.0 million within a period of 12 months from June 2004 in milestones and research support; $4.0 million over the subsequent 24 months in research support; and up to $27.0 million in additional milestone payments. TopoTarget is expected to receive royalties from Curagen based on sales of PXD101 outside of Europe, and Curagen expects to receive reciprocal royalties from TopoTarget based on sales of PXD101 in Europe....See full deal structure in Biomedtracker
Partners: Onxeo SA Pint Pharma International S.A.,
Additional information available to subscribers only: